耐碳青霉烯类肠杆菌科细菌感染的抗菌治疗指南
Guidelines for Antibacterial Treatment of Carbapenem-Resistant Enterobacterales Infections.
作者信息
Park Se Yoon, Baek Yae Jee, Kim Jung Ho, Seong Hye, Kim Bongyoung, Kim Yong Chan, Yoon Jin Gu, Heo Namwoo, Moon Song Mi, Kim Young Ah, Song Joon Young, Choi Jun Yong, Park Yoon Soo
机构信息
Division of Infectious Diseases, Department of Internal Medicine, Hanyang University Seoul Hospital, Seoul, Korea.
Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
出版信息
Infect Chemother. 2024 Sep;56(3):308-328. doi: 10.3947/ic.2024.0038. Epub 2024 Aug 2.
Abstract
This guideline aims to promote the prudent use of antibacterial agents for managing carbapenem-resistant Enterobacterales (CRE) infections in clinical practice in Korea. The general section encompasses recommendations for the management of common CRE infections and diagnostics, whereas each specific section is structured with key questions that are focused on antibacterial agents and disease-specific approaches. This guideline covers both currently available and upcoming antibacterial agents in Korea.
摘要
本指南旨在促进韩国临床实践中谨慎使用抗菌药物来治疗耐碳青霉烯类肠杆菌科细菌（CRE）感染。总则部分包括常见CRE感染管理及诊断的建议，而每个具体章节则围绕聚焦抗菌药物和疾病特异性方法的关键问题展开。本指南涵盖了韩国目前可用及即将上市的抗菌药物。
相似文献
1
Guidelines for Antibacterial Treatment of Carbapenem-Resistant Enterobacterales Infections.
Infect Chemother. 2024 Sep;56(3):308-328. doi: 10.3947/ic.2024.0038. Epub 2024 Aug 2.
2
Continuous Evolution: Perspective on the Epidemiology of Carbapenemase Resistance Among Enterobacterales and Other Gram-Negative Bacteria.
Infect Dis Ther. 2021 Mar;10(1):75-92. doi: 10.1007/s40121-020-00395-2. Epub 2021 Jan 25.
3
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
Clin Infect Dis. 2021 Apr 8;72(7):e169-e183. doi: 10.1093/cid/ciaa1478.
4
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
Clin Infect Dis. 2021 Apr 8;72(7):1109-1116. doi: 10.1093/cid/ciab295.
5
Systematic Analysis of Mobile Genetic Elements Mediating β-Lactamase Gene Amplification in Noncarbapenemase-Producing Carbapenem-Resistant Bloodstream Infections.
mSystems. 2022 Oct 26;7(5):e0047622. doi: 10.1128/msystems.00476-22. Epub 2022 Aug 29.
6
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
Clin Infect Dis. 2022 Aug 25;75(2):187-212. doi: 10.1093/cid/ciac268.
7
Risk Factors for Carbapenem-Resistant Clinical Treatment Failure.
Microbiol Spectr. 2023 Feb 14;11(1):e0264722. doi: 10.1128/spectrum.02647-22. Epub 2023 Jan 9.
8
Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.
Clin Infect Dis. 2022 Jul 6;74(12):2089-2114. doi: 10.1093/cid/ciab1013.
9
Biological studies of the activity of Manuka honey against Carbapenem-resistant Enterobacterales (CRE) bacteria.
Saudi Med J. 2024 Aug;45(9):876-887. doi: 10.15537/smj.2024.45.9.20240153.
10
Carbapenem use in extended-spectrum cephalosporin-resistant Enterobacterales infections in US hospitals and influence of IDSA guidance: a retrospective cohort study.
Lancet Infect Dis. 2024 Aug;24(8):856-867. doi: 10.1016/S1473-3099(24)00149-X. Epub 2024 Apr 25.
引用本文的文献
1
Characterization and genome analyses of the novel phages targeting extraintestinal Escherichia coli clones ST131 and ST410.
Int Microbiol. 2025 Jun 20. doi: 10.1007/s10123-025-00686-z.
2
"Global divide in carbapenem resistance and hypervirulence of Klebsiella pneumonia: comparing trends in India and developed nations"- a comprehensive review.
J Antibiot (Tokyo). 2025 Jun 3. doi: 10.1038/s41429-025-00833-8.
本文引用的文献
1
Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.
Clin Infect Dis. 2023 Jul 18. doi: 10.1093/cid/ciad428.
2
Korean Guidelines for Use of Antibiotics for Intra-abdominal Infections in Adults.
Infect Chemother. 2022 Dec;54(4):812-853. doi: 10.3947/ic.2022.0156.
3
A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0059122. doi: 10.1128/aac.00591-22. Epub 2022 Sep 20.
4
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
Clin Infect Dis. 2022 Aug 25;75(2):187-212. doi: 10.1093/cid/ciac268.
5
Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms.
J Microbiol Immunol Infect. 2022 Jun;55(3):359-386. doi: 10.1016/j.jmii.2022.02.001. Epub 2022 Mar 16.
6
Risk factors for infection and mortality caused by carbapenem-resistant Klebsiella pneumoniae: A large multicentre case-control and cohort study.
J Infect. 2022 May;84(5):637-647. doi: 10.1016/j.jinf.2022.03.010. Epub 2022 Mar 14.
7
Evaluating NG-Test CARBA 5 Multiplex Immunochromatographic and Cepheid Xpert CARBA-R Assays among Carbapenem-Resistant Isolates Associated with Bloodstream Infection.
Microbiol Spectr. 2022 Feb 23;10(1):e0172821. doi: 10.1128/spectrum.01728-21. Epub 2022 Jan 12.
8
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).
Clin Microbiol Infect. 2022 Apr;28(4):521-547. doi: 10.1016/j.cmi.2021.11.025. Epub 2021 Dec 16.
9
Risk Factors for Mortality in Patients with Carbapenemase-producing and bacteremia.
Infect Chemother. 2021 Sep;53(3):528-538. doi: 10.3947/ic.2021.0083.
10
Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates.
J Antimicrob Chemother. 2021 Nov 12;76(12):3125-3134. doi: 10.1093/jac/dkab306.
Zotero 插件